Sotorasib
Sotorasib
Definition
An orally available inhibitor of the specific KRAS mutation, p.G12C, with potential antineoplastic activity. Upon oral administration, sotorasib selectively targets, binds to and inhibits the activity of the KRAS p.G12C mutant. This may inhibit growth in KRAS p.G12C-expressing tumor cells. The KRAS p.G12C mutation is seen in some tumor cell types and plays a key role in tumor cell proliferation.
Also known as AMG 510, AMG-510, AMG510, Lumakras, Lumykras, SOTORASIB — per NCIT
Also identified as
- ATC L01XX73 per RXNORM
- NCIT NCIT:C154287 per NCIT
- SCTID 1162482008 per RXNORM
- SCTID 1162509004 per RXNORM
- UNII 2B2VM6UC8G per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Non-small cell lung carcinoma | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Lungs | may treat a disease of this organ | DERIVED · CC BY 4.0 |
1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.